Holen Sie sich die Stockscreener-App
516.56
0.65%
3.35
Handel nachbörslich:
516.56
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$513.21
Offen:
$513.75
24-Stunden-Volumen:
153.39K
Relative Volume:
0.46
Marktkapitalisierung:
$11.93B
Einnahmen:
$1.13B
Nettoeinkommen (Verlust:
$-309.44M
KGV:
-40.36
EPS:
-12.8001
Netto-Cashflow:
$-275.41M
1W Leistung:
-2.81%
1M Leistung:
+0.86%
6M Leistung:
+11.83%
1J Leistung:
+22.12%
1-Tages-Spanne:
$511.31
$523.96
1-Wochen-Bereich:
$502.62
$536.04
52-Wochen-Spanne:
$393.61
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
516.56 | 11.93B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs - Moomoo
MDGL Reinstated by Goldman Sachs -- Price Target Announced at $7 - gurufocus.com
Goldman Sachs assumes Madrigal Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
Goldman Sachs Reinitiates Coverage on Madrigal Pharmaceuticals (MDGL) with Buy Rating and $704 Price Target - gurufocus.com
Madrigal Pharmaceuticals Inc (YDO1.DU) valuation measures and financial statistics - Yahoo Finance Australia
MDGL Initiates Coverage On Citigroup -- Price Target Announced a - gurufocus.com
Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725 - Moomoo
Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target - Yahoo Finance
Madrigal Pharmaceuticals stock falls 1.80 percent as valuation stays high - AD HOC NEWS
(MDGL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Madrigal Pharmaceuticals stock trades around 531 dollars as institutional interest stays strong - AD HOC NEWS
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook on a Biotech Powerhouse with 27.57% Potential Upside - DirectorsTalk Interviews
Madrigal Pharmaceuticals Inc (YDO1.SG) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Madrigal Pharmaceuticals stock holds above 530 dollars after recent ownership change - AD HOC NEWS
Madrigal Pharmaceuticals stock holds near $531 after fresh analyst data - AD HOC NEWS
How New Headquarters At Madrigal Pharmaceuticals Stock Has Changed Its Investment Story - simplywall.st
Madrigal Pharmaceuticals Inc (YDO1) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - simplywall.st
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - Stock Titan
Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - Stock Titan
September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq
Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - The Manila Times
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 27% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Madrigal Pharmaceuticals (MDGL) Declines 1.83% to $533.76 as Consolidation ContinuesShort Setup Alerts - careplusvn.com
Madrigal Grants Stock Awards to 13 New Employees - MyChesCo
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Report: Analysts See 31% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - Stock Titan
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - Stock Titan
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):